Jazz Pharmaceuticals plc (NASDAQ: JAZZ) is -20.60% lower on its value in year-to-date trading and has touched a low of $95.49 and a high of $148.06 in the current 52-week trading range. The question becomes, what are the chances the stock will make a comeback and enjoy potential growth. Why not look at analysts view on what the future holds for the stock. The JAZZ stock was last observed hovering at around $98.41 in the last trading session, with the day’s loss setting it -0.63%.
Currently trading at $97.78, the stock is -8.94% and -19.26% below its SMA20 and SMA50 respectively. However, with a daily trading volume of 1.22 million and changing -0.64% at the moment leaves the stock -17.66% off its SMA200. JAZZ registered -12.08% loss for a year compared to 6-month loss of -12.25%.
The stock witnessed a -11.21% gain in the last 1 month and extending the period to 3 months gives it a -18.71%, and is -18.55% down over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 5.18% over the week and 4.29% over the month.
Jazz Pharmaceuticals plc (JAZZ) has around 2800 employees, a market worth around $6.03B and $4.06B in sales. Current P/E ratio is 13.19 and Fwd P/E is 4.54. Profit margin for the company is 11.86%. Distance from 52-week low is 2.40% and -33.96% from its 52-week high. The company has generated returns on investments over the last 12 months (5.05%).
The EPS is expected to shrink by -70.65% this year.
Jazz Pharmaceuticals plc (JAZZ) Top Institutional Holders
The shares outstanding are 61.62M, and float is at 58.84M with Short Float at 9.09%.
The top institutional shareholder in the company is VANGUARD GROUP INC with over 6.32 million shares valued at $674.82 million. The investor’s holdings represent 10.0549% of the JAZZ Shares outstanding. As of 2024-06-30, the second largest holder is BLACKROCK INC. with 6.15 million shares valued at $655.94 million to account for 9.7735 of the shares outstanding. The other top investors are LSV ASSET MANAGEMENT which holds 2.48 million shares representing 3.9448% and valued at over $264.75 million, while CAPITAL WORLD INVESTORS holds 3.2117 of the shares totaling 2.02 million with a market value of $215.55 million.
Jazz Pharmaceuticals plc (JAZZ) Insider Activity
The most recent transaction is an insider sale by COZADD BRUCE C, the company’s Chairman & CEO. SEC filings show that COZADD BRUCE C sold 1,000 shares of the company’s common stock on May 01 ’25 at a price of $116.35 per share for a total of $0.12 million. Following the sale, the insider now owns 0.44 million shares.
Jazz Pharmaceuticals plc disclosed in a document filed with the SEC on May 02 ’25 that COZADD BRUCE C (Chairman & CEO) sold a total of 500 shares of the company’s common stock. The trade occurred on May 02 ’25 and was made at $120.00 per share for $60000.0. Following the transaction, the insider now directly holds 0.44 million shares of the JAZZ stock.
Still, SEC filings show that on May 01 ’25, COZADD BRUCE C (Officer) Proposed Sale 1,500 shares at an average price of $117.57 for $0.18 million. The insider now directly holds shares of Jazz Pharmaceuticals plc (JAZZ).
